The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
About
CIO supports a spectrum discovery research from atoms to humans with a focus on improving human health.
Read moreWhat's new for Oxford Cancer
-
Dr Peter Wan Awarded Pancreatic Cancer UK Fellowship to Develop New Immunotherapy for Pancreatic Cancer
9 October 2025
-
PSA testing patterns in England raise concerns about overtesting
9 October 2025
-
CRUK Oxford Development Fund - now open for applications!
6 October 2025
-
Embracing Pride to assess perceptions of cancer research involvement among the LGBTQ+ community and improve inclusivity
30 September 2025
-
Two world firsts in myeloma trials at OUH
23 September 2025
CIO News
CIO and Dunn School Join Forces to Pioneer Vaccines Against Childhood Cancers
9 October 2025
A new partnership between Alice’s Arc, the Centre for Immuno-Oncology in the Nuffield Department of Medicine and the Sir William Dunn School of Pathology will pioneer the development of a bespoke mRNA vaccine to improve treatment outcomes for children with rhabdomyosarcoma, a rare and aggressive form of soft tissue cancer.
A Day of Science, Creativity, and Connection at the CIO Away Day
6 August 2025
The Centre for Immuno-Oncology came together last week for a vibrant and inspiring CIO Away Day. In the beautiful Rhodes house we enjoyed a full day of science, creativity, reflection, and community.
Professor Andrew McMichael elected to the US National Academy of Sciences
20 May 2025
The National Academy of Sciences (NAS) in the US announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and is considered one of the highest honours that a scientist can receive.
Oxford Immunology Symposium 2025
3 February 2025
The BSI Oxford Immunology Group, in collaboration with the University of Oxford Immunology Network, is pleased to present a one-day showcase of the fantastic immunology research happening across Oxford.
Latest publications
-
Targeting MHC-E as a new strategy for vaccines and immunotherapeutics
Journal article
Frueh K. et al, (2025), Nature Reviews Immunology
-
Nanotechnology for immuno-oncology.
Journal article
Grippin AJ. et al, (2025), Nature cancer
-
Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T-cell responses and anti-tumor immunity by targeting conventional type 1 dendritic cells.
Journal article
Huete-Carrasco J. et al, (2025), Immunology and cell biology
-
T cell engagers: expanding horizons in oncology and beyond.
Journal article
Albayrak G. et al, (2025), Br J Cancer
-
Atom-level mechanism of tapasin-independent peptide editing by Major Histocompatibility Complex class I molecules
Preprint
Turner S. et al, (2025)
-
Strict advantage of complex quantum theory in a communication task
Journal article
Elliott TJ., (2025), Physical Review A, 111
-
Antigen-presenting mast cells are new players in breast cancer immunotherapy.
Journal article
Luri-Rey C. et al, (2025), Nature medicine
-
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade.
Journal article
Lee CY. et al, (2025), Cancer immunology research
-
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Journal article
Ruiz-Fernández de Córdoba B. et al, (2025), Signal transduction and targeted therapy, 10
-
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
Journal article
Alsina M. et al, (2025), Clin Cancer Res
-
Supplemental Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplementary Figure S1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
Oxford Talks
-
Saturday, 11 October 2025, 9.45am to 10.30am
Venue: Examination Schools, 75-81 High Street OX1 4BG
-
Saturday, 11 October 2025, 10.30am to 1.30pm
Venue: Examination Schools, 75-81 High Street OX1 4BG
-
Saturday, 11 October 2025, 3pm to 4pm
Speakers: Eli Erlick
-
Monday, 13 October 2025, 9am to 11am
Speakers: Matthieu Miossec
Venue: Big Data Institute, Old Road Campus OX3 7LF
-
Monday, 13 October 2025 to Thursday, 16 October 2025, 9am - 5pm